TAGS: Skin Care
Natural/ Organic
Bayer and Azitra Inc. have announced a joint development agreement to collaborate in the identification and characterization of skin microbiome bacteria. Skin microbiome plays a crucial role in maintaining and restoring healthy human skin. Azitra and Bayer to develop new natural skin care products based on suited skin microbiome bacteria.
Natural Products Based on Skin Microbiome
The partnership will leverage Azitra’s proprietary panel of Staphylococcus epidermidis strains to identify potential candidates for the treatment of adverse skin conditions and diseases. Based on the results of the research partnership, Bayer plans to develop selected Staphylococcus epidermidis strains into new natural skin care products under a future license agreement.
“
The skin microbiome offers a promising platform for the development and commercialization of natural skin care products more and more people are looking for. As Bayer is committed to the development of science-based consumer health products through our own research as well as external partnerships, we’re delighted to collaborate with Azitra,” commented Heiko Schipper, member of the board of management of Bayer AG and president of Bayer Consumer Health
Prospective areas of application include medicated skin care products for sensitive, eczema-prone skin as well as therapeutic products for skin diseases such as atopic dermatitis.
Skin Microbiome Contributes to Protection
Recent scientific publications suggest that microorganisms such as bacteria and especially skin-friendly bacteria, commonly referred to as skin microbiome, can significantly contribute to the protection of the skin from hostile invasions.
Additional positive effects include supporting the recovery from skin diseases such as atopic dermatitis, acne and rosacea, and may also accelerate wound healing.
“
The company has already demonstrated tolerability of a selected Staphylococcus epidermidis strain in healthy volunteers and is now planning to start the clinical demonstration of efficacy,” added Schipper.
Bayer will actively contribute to the research collaboration by providing suitable topical formulations that are able to maintain Staphylococcus epidermidis viability while showing excellent skin compatibility and sensorial performance.
"
We are strongly committed to the potential of the microbiome to provide significant benefits for improved skin health and appearance and by working together with Bayer I am confident we can deliver on the promise of this technology," stated Richard Andrews, president and CEO of Azitra.
Source: Bayer